Clinical Trial

Neoadjuvant Immunoradiotherapy in Head & Neck Cancer

Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to test the safety of neoadjuvant immunoradiotherapy as a safe means of down-staging Head and Neck Squamous Cell Carcinoma (HNSCC) prior to surgical resection.
Protocol Amendment History 12 amendments
This ClinicalTrials.gov record has been amended 12 times since 2017-08-10; most recent amendment 2026-07-21.
Status change: Recruiting → Active, Not Recruiting 2021-05-19
Status change: Not Yet Recruiting → Recruiting 2018-01-23
Trial Details
NCT Number NCT03247712
Lead Sponsor Providence Health & Services
Collaborators: Providence Cancer Center, Earle A. Chiles Research Institute
Conditions Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
Enrollment 22 participants
Start Date 2018-01-15
Primary Completion 2020-02-13 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-07-23